Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Mesoblast Financial Results Webcast for Period Ended March 31, 2019

GlobeNewswire May 30, 2019

Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease

GlobeNewswire May 29, 2019

Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy

GlobeNewswire May 23, 2019

Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 17, 2019

Mesoblast to Present at Upcoming Global Life Sciences Conference in London

GlobeNewswire April 5, 2019

Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients

GlobeNewswire March 26, 2019

Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa

GlobeNewswire March 25, 2019

U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman

GlobeNewswire March 22, 2019

Mesoblast Features at Upcoming U.S. Investor Conferences

GlobeNewswire March 13, 2019

Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018

GlobeNewswire February 20, 2019

Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure

GlobeNewswire February 19, 2019

Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018

GlobeNewswire February 13, 2019

New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast — Consolidated Revenues, Company Growth, and Expectations for 2019

GlobeNewswire February 4, 2019

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

GlobeNewswire January 14, 2019

Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco

GlobeNewswire January 7, 2019

Phase 3 Trial of Mesoblast’s Cell Therapy in Chronic Heart Failure Completes Recruitment

GlobeNewswire January 7, 2019

Mesoblast Corporate Review

GlobeNewswire December 28, 2018

Mesoblast to Present at 2019 Biotech Showcase in San Francisco

GlobeNewswire December 24, 2018

Mesoblast Makes Executive Appointment to Drive Product Commercialization

GlobeNewswire December 19, 2018

Meetings Held With FDA Support Mesoblast’s Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD

GlobeNewswire December 13, 2018